7 Biotechnology Stocks to Buy Now

by Portfolio Grader | October 30, 2013 11:15 am

This week, seven Biotechnology stocks are improving their overall ratings on Portfolio Grader[1]. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This week, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA[2]) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock[3].

The rating of Neurocrine Biosciences, Inc. (NASDAQ:NBIX[4]) moves up this week, rising from a C to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock[5].

Array BioPharma (NASDAQ:ARRY[6]) shows solid improvement this week. The company’s rating rises from a C to a B. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock[7].

This week, Celldex Therapeutics, Inc. (NASDAQ:CLDX[8]) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock[9].

BioSpecifics Technologies (NASDAQ:BSTC[10]) boosts its rating from a C to a B this week. BioSpecifics Technologies is a biopharmaceutical company that has been involved in the development of injectable collagenase for multiple indications. For more information, get Portfolio Grader’s complete analysis of BSTC stock[11].

Insmed Incorporated’s (NASDAQ:INSM[12]) ratings are looking better this week, moving up to a B from last week’s C. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock[13].

Neuralstem, Inc. (AMEX:CUR[14]) is seeing ratings go up from a C last week to a B this week. Neuralstem is a biotherapeutics company utilizing its Human Neural Stem Cell technology to develop cures for diseases of the CNS. For more information, get Portfolio Grader’s complete analysis of CUR stock[15].

Louis Navellier’s proprietary Portfolio Grader[16] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[17].

Source URL: https://investorplace.com/2013/10/7-biotechnology-stocks-to-buy-now-aria-nbix-arry-2/

---